Federal grants to Molecular Express, Inc
Molecular Express, Inc in Compton, California received $5.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cardiovascular Diseases Research, with $4.2 million. In fiscal 2025 it was awarded $999,784.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.1 million
- Awards4
- Awarded in FY 2025$999,784
- Largest award$2.2 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $956,889 |
| FY 2022 | 3 | $1.8 million |
| FY 2023 | 1 | $299,779 |
| FY 2024 | 1 | $999,853 |
| FY 2025 | 1 | $999,784 |
Programs that fund Molecular Express, Inc
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 2 | $4.2 million |
| Allergy and Infectious Diseases Research | 2 | $898,075 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $5.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Non-clinical development of a synthetic lung surfactant for treatment of nrds - project summary/abstract surfactant deficiency in preterm infants causes the neonatal respiratory distress syndrome (NRDS). Nrds directly causes mortality and morbidity. Nrds also increases the risk of intraventricular h | Cardiovascular Diseases Research | June 16, 2021 | $2.2 million |
| Preclinical development of a ME-1001, a synthetic lung surfactant - project summary/abstract surfactant deficiency in preterm infants causes the neonatal respiratory distress syndrome (NRDS). Nrds directly causes mortality and morbidity. Nrds also increases the risk of intraventricular hemorrhage, b | Cardiovascular Diseases Research | May 8, 2024 | $2.0 million |
| Vesivax vaccine formulation against neisseria gonorrhoeae - project summary the principal goal of this project is to develop a vesivax®-based vaccine against neisseria gonorrhoeae (NG). The studies proposed in this sbir phase i application will be focused on co-formulating an newly identified surfac | Allergy and Infectious Diseases Research | February 17, 2022 | $599,596 |
| Niclosamide formulations for the treatment of influenza infections - project summary the principal goal of this project is to demonstrate that the fda-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections | Allergy and Infectious Diseases Research | July 8, 2022 | $298,479 |
Questions people ask
How much federal grant money does Molecular Express, Inc get?
$5.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Molecular Express, Inc the most?
The Department of Health and Human Services, with $5.1 million in 4 awards.
What is Molecular Express, Inc's largest federal grant?
$2.2 million under Cardiovascular Diseases Research, with its first action in the period on June 16, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Molecular Express, Inc?
Its largest are Cardiovascular Diseases Research and Allergy and Infectious Diseases Research.
Other grant recipients in Compton
- Compton College
- City of Compton
- The R.O.A.D.S. Foundation, Inc.
- Entrenous Community Empowerment, Inc.
- De Novo Health Care, Inc
- Aghaby Comprehensive Community Health Center
Largest federal grant recipients in California · Federal grants in California